Research programme: mTOR/PI3K inhibitors - Roche
Alternative Names: PI-103Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator The Institute of Cancer Research
- Class Pyrimidines
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 09 Sep 2013 Preclinical development is ongoing in United Kingdom
- 21 Apr 2009 Preclinical pharmacodynamics data in Cancer presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)